Navigation Links
d'Oliveira & Associates Releases New Byetta Infographic on Potential Kidney and Pancreas Health Risks Associated with the Drug
Date:3/24/2013

(PRWEB) March 24, 2013

Approved by the FDA in April 2005, Byetta is a type-2 diabetes drug used to control glucose levels. Adverse Events, an organization that standardizes FDA adverse event reports, has processed 38,730 adverse events concerning Byetta and 1,733 of these reports allege a link between the drug and cases of pancreatitis (i). According to the USA Today article, “Popular diabetes drugs may raise pancreatic cancer risk, study suggests,” pancreatitis and cancer were two of the health concerns raised by a recent medical study (ii). The article goes on to report a study completed by the Research Center at the University of California, Los Angeles that found a six-fold increase of pancreatitis in patients taking Byetta or Januvia and it also increased the risk of pancreatic cancer by 2.9 times and thyroid cancer in patients taking the drug (ii).

Bloomberg reported the results of a Byetta medical study published in the Journal of the American Medical Association for Internal Medicine; the study followed 1,269 patients with type-2 diabetes who filled at least one prescription for a diabetes drug in a three-year period (iii). Out of the 145 patients who developed pancreatitis, 87 of them were taking Byetta or Januvia, the study suggested that Byetta and Januvia doubled the risk of pancreatitis compared to other diabetes drugs (iii). The study’s author, Dr. Sonal Singh, told Bloomberg that, “we really need to know more about these drugs as pancreatitis is on the pathway to pancreatic cancer (iii).”

The Byetta infographic provides a timeline detailing major events in the development of the drug. For example, from April 2005 until October 2008, the FDA received 78 complaints of kidney damage in patients using Byetta, 62 of these complaints reported kidney failure (iv). Visit the Byetta section of d’Oliveira & Associates or view the infographic HERE.

If you or a loved one has suffered pancreatic, liver, or thyroid cancer, after taking Byetta, you may want to speak with a personal injury lawyer. A dangerous drug lawyer familiar with the diabetes injection can investigate a legal claim. d’Oliveira & Associates is working with some of the most experienced Byetta lawyers in the country, who are handling these cases. And, there is no fee until you receive a Byetta settlement or award.

Please contact the law offices of d'Oliveira & Associates at 1-800-992-6878 or fill out a contact form for a free legal consultation.

(i) http://www.adverseevents.com/drugdetail.php?AEDrugID=1260&BrandName=BYETTA
(ii) http://usatoday30.usatoday.com/news/health/medical/health/medical/story/2011-09-23/Popular-diabetes-drugs-may-raise-pancreatic-cancer-risk-study-suggests/50531776/1
(iii) http://www.bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
(iv) http://www.fda.gov/safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm188703.htm

Read the full story at http://www.prweb.com/releases/2013/3/prweb10548949.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. d'Oliveira & Associates Offers “No Win - No Fee Promise” on Topamax Cases
2. d'Oliveira & Associates Releases Zimmer Knee Infographic Providing Important Safety Information on High-Flex Knees
3. d'Oliveira & Associates Helps Massachusetts Man Receive $100,000 in Auto Accident Settlement
4. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Mirena IUD Cases
5. d'Oliveira & Associates Releases Fresenius Infographic about the FDA Recall of NaturaLyte and GranuFlo
6. D'Oliveira & Associates Now Offers a No Win No Fee Promise in Zithromax Cases
7. d'Oliveira & Associates Helps Fall River, MA Teenager Receive $38,500 in Auto Accident Settlement
8. d'Oliveira & Associates Notes the Announcement of Zoloft Birth Defects Multidistrict Litigation (MDL) Set to Start in Mid-September 2014
9. The Law Firm of d'Oliveira and Associates Now Offers a No Win - No Free Promise in Nexium Cases
10. The Law Firm of d'Oliveira & Associates Now Offers a No Win - No Fee Promise in Fosamax Cases
11. d'Oliveira & Associates Helps Newport Woman Receive $150,000 Settlement for Auto Accident; Case: MI-11889
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/20/2017)... , ... January 20, 2017 , ... Michael and Betsy ... Farber Cancer Institute. For Betsy, the clinical trial has been life-saving as she ... not worsened. , Betsy Brauser was diagnosed with ovarian cancer in 2009. She ...
(Date:1/20/2017)... ... ... “Mary Magdalene: Grace is Greater than Sin”: a unique and memorable piece ... “Mary Magdalene: Grace is Greater than Sin” is the creation of published author, Brenda ... women who had little knowledge of the female characters portrayed in the Holy Bible. ...
(Date:1/20/2017)... ... , ... “I Forgive You”: a fine examination of how God handles sin, including how ... published author, Stephen Miller, who, for over ten long years has been waiting to release ... Trinidad and Tobago, he has been serving the Lord for over twenty years, and he ...
(Date:1/20/2017)... ... ... enchanting tale that teaches children the true meaning of Christmas. “Journey to Christmas” is the ... devoted woman of faith. , “Becoming a parent changes you. In my case, the ... years, but actually doing it might have been a while in coming if it hadn’t ...
(Date:1/20/2017)... ... 2017 , ... “God's Miracle Man: Against All Odds”: an inspiring affirmation ... author, Keith C. A. Tucker, son of Minister Delores Pinnock and a Jamaican native ... Mark Hardy , “While sitting up in bed, I felt a pounding headache. It ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... January 19, 2017 ... Oncology & Haematology, 2016;12(Suppl 2):3-8; http://www.touchoncology.com/articles/optimising-clinical-outcomes-gastrointestinal-cancers-through-inhibiting-angiogenesis-and ... ... Published recently in a supplement to ... from touchONCOLOGY, an article by James Gilbart ...
(Date:1/19/2017)... 2017 ViewRay, Inc. (Nasdaq: VRAY) announced today that ... research in Germany , has purchased ... the University Clinic Heidelberg as part of its initiative ... program will be headed by Medical Director and Professor ... at the German Cancer Research Center (DKFZ), the Heidelberg ...
(Date:1/19/2017)... PALO ALTO, Calif. , Jan. 19, 2017 /PRNewswire/ ... scientific research, is excited to announce that the ... Project: Cancer Biology  (RP:CB) have been published in ... science, this project represents the first practical evaluation ... that result in reproducible studies. Unlike other assessments ...
Breaking Medicine Technology: